Overview
Valine is a branched-chain essential amino acid that has stimulant activity. It promotes muscle growth and tissue repair. It is a precursor in the penicillin biosynthetic pathway.
Indication
Promotes mental vigor, muscle coordination, and calm emotions. May also be of use in a minority of patients with hepatic encephalopathy and in some with phenylketonuria.
Associated Conditions
- Hepatic Encephalopathy (HE)
- Septic Encephalopathy
- Hepatic coma
- Hypercatabolism
- Uremic Encephalopathy
Clinical Trials
Title | Posted | Study ID | Phase | Status | Sponsor |
|---|---|---|---|---|---|
2023/01/30 | Early Phase 1 | Recruiting | |||
2018/05/01 | Phase 1 | Completed |
FDA Drug Approvals
Approved Product | Manufacturer | NDC Code | Route | Strength | Effective Date |
|---|---|---|---|---|---|
| Baxter Healthcare Corporation | 0338-0184 | INTRAVENOUS | 464 mg in 100 mL | 4/13/2021 | |
| Baxter Healthcare Company | 0338-0210 | INTRAVENOUS | 464 mg in 100 mL | 9/21/2020 | |
| Baxter Healthcare Corporation | 0338-0210 | INTRAVENOUS | 464 mg in 100 mL | 9/21/2020 | |
| Baxter Healthcare Corporation | 0338-1089 | INTRAVENOUS | 247 mg in 100 mL | 4/13/2021 | |
| Baxter Healthcare Corporation | 0338-1099 | INTRAVENOUS | 290 mg in 100 mL | 4/13/2021 | |
| ICU Medical Inc. | 0990-7171 | INTRAVENOUS | 750 mg in 100 mL | 5/4/2022 | |
| Baxter Healthcare Corporation | 0338-0194 | INTRAVENOUS | 464 mg in 100 mL | 4/13/2021 | |
| Baxter Healthcare Company | 0338-1147 | INTRAVENOUS | 290 mg in 100 mL | 9/21/2020 | |
| Baxter Healthcare Corporation | 0338-1147 | INTRAVENOUS | 290 mg in 100 mL | 9/21/2020 | |
| Baxter Healthcare Company | 0338-1142 | INTRAVENOUS | 160 mg in 100 mL | 9/21/2020 |
EMA Drug Approvals
Approved Product | Authorization Holder | Status | Issued Date |
|---|---|---|---|
| No EMA approvals found for this drug. | |||
HSA Drug Approvals
Approved Product | Manufacturer | Approval Number | Dosage Form | Strength | Approval Date |
|---|---|---|---|---|---|
| NUTRIFLEX® OMEGA PLUS EMULSION FOR INFUSION | SIN15468P | INJECTION, EMULSION | 2.496g/1000ml | 4/23/2018 | |
| SYNTHAMIN 17 WITHOUT ELECTROLYTES 10% AMINO ACID INTRAVENOUS INFUSION | SIN09992P | INJECTION | 5.80 g/l | 9/15/1998 | |
| NUTRIFLEX® OMEGA SPECIAL B. BRAUN EMULSION FOR INFUSION | SIN16734P | INJECTION, EMULSION | 3.604g/1000ml | 3/7/2023 | |
| NUTRINEAL PD4 WITH 1.1% AMINO ACID SOLUTION | SIN09353P | SOLUTION, STERILE | 1.393 g/l | 5/27/1997 | |
| SmofKabiven Emulsion for Infusion | SIN14286P | INJECTION, EMULSION | 6.2g /1000ml | 1/8/2013 | |
| KABIVEN PERIPHERAL EMULSION FOR INFUSION | SIN11718P | INJECTION | 1.5 g/l | 11/16/2001 | |
| OLICLINOMEL N7-1000 E EMULSION FOR INFUSION | SIN12539P | EMULSION | 2.32 g/l | 5/6/2004 | |
| PERIOLIMEL N4E Emulsion for Infusion | SIN16888P | EMULSION | 1.62g/L | 10/20/2023 | |
| TROPHAMINE INJECTION 10% | SIN07846P | INJECTION | 0.78 g/100 ml | 9/12/1994 | |
| AMINOPLASMAL B.BRAUN 10% E SOLUTION FOR INFUSION | SIN15411P | INFUSION, SOLUTION | 6.20g/1000ml | 1/23/2018 |
NMPA Drug Approvals
Approved Product | Company | Approval Number | Drug Type | Dosage Form | Approval Date |
|---|---|---|---|---|---|
| No NMPA approvals found for this drug. | |||||
PPB Drug Approvals
Approved Product | Registration No. | Company | Licence No. | Strength | Registration Date |
|---|---|---|---|---|---|
| LA-FLAMING INJ. | N/A | N/A | N/A | 1/28/2010 | |
| VAMINOLACT I.V. SOLUTION | N/A | N/A | N/A | 10/14/1992 | |
| OLIMEL N9E EMULSION FOR INFUSION | N/A | N/A | N/A | 10/24/2013 | |
| PAN-AMIN G INJ | N/A | N/A | N/A | 5/17/1979 | |
| PAN-AMIN G SOLUTION FOR INFUSION 500ML | N/A | otsuka pharmaceutical (h.k.) limited | N/A | N/A | 4/5/2012 |
| NUTRIFLEX OMEGA PLUS EMULSION FOR INFUSION | N/A | N/A | N/A | 1/11/2012 | |
| LIVACT GRANULES | N/A | N/A | N/A | 6/6/2014 | |
| AMINOGEN-S SOLUTION FOR INFUSION | N/A | wings pharmaceutical ltd | N/A | N/A | 8/15/2013 |
| PAN-VASOL SOLUTION FOR INJECTION | N/A | N/A | N/A | 4/23/2011 | |
| NUTRINEAL PD-4 W/1.1% AA PERITONEAL DIAL SOLN | N/A | N/A | N/A | 12/31/2003 |
TGA Drug Approvals
Approved Product | ARTG ID | Sponsor | Registration Type | Status | Registration Date |
|---|---|---|---|---|---|
| SYNTHAMIN 17 Amino acid 10% with Electrolytes and Glucose 25% 1000mL injection AHB6350 | 19609 | Medicine | A | 9/30/1991 | |
| AMINOVEN amino acid 10% solution for infusion 500 mL bottle | 117659 | Medicine | A | 10/22/2007 | |
| SMOFKABIVEN amino acids 5.1% / lipids 3.8% / glucose 12.7% / electrolytes 0.7% emulsion for intravenous infusion bag 1970 mL | 180546 | Medicine | A | 1/9/2012 | |
| OLICLINOMEL N4-550 E 1000 mL IV emulsion for infusion with electrolytes bag | 136599 | Medicine | A | 9/4/2007 | |
| OLICLINOMEL N4-550 E 2500 mL IV emulsion for infusion with electrolytes bag | 141396 | Medicine | A | 9/4/2007 | |
| OLIMEL N5-860E Emulsion for intravenous infusion | 197417 | Medicine | A | 8/9/2013 | |
| Olimel N12-640 emulsion for intravenous infusion bag. | 303755 | Medicine | A | 7/1/2019 | |
| MUSASHI SLEEP RECOVERY | 308710 | Medicine | A | 8/28/2018 | |
| SMOFKABIVEN LOW OSMO amino acids 2.5%, electrolytes 0.4%, lipids 3.5% & glucose 6.8% emulsion for intravenous infusion 2500 mL biofine bag | 329619 | Medicine | A | 8/27/2020 | |
| ElementAll Diet | 447331 | Medicine | A | 5/1/2024 |
Health Canada Drug Approvals
Approved Product | Company | DIN | Dosage Form | Strength | Market Date |
|---|---|---|---|---|---|
| 4.25% TRAVASOL AMINO ACID INJECTION WITHOUT ELECTRLYTES IN 10% DEXTROSE | baxter corporation clintec nutrition division | N/A | Solution - Intravenous | 246.5 MG / 100 ML | 12/31/1996 |
| 4.25% TRAVASOL AMINO ACID INJECTION WITH ELECTROLYTES IN 10% DEXTROSE | baxter corporation clintec nutrition division | N/A | Solution - Intravenous | 246.5 MG / 100 ML | 12/31/1996 |
| 2.75%TRAVASOL AMINO ACID INJ.W.ELEC.W.5%DEX. | clintec nutrition company | 02143240 | Liquid - Intravenous | 159.5 MG / 100 ML | 12/31/1996 |
| 4.25%TRAVASOL AMINO ACID INJ.W.ELECW.5%DEX. | clintec nutrition company | 02143224 | Liquid - Intravenous | 246.5 MG / 100 ML | 12/31/1996 |
| 5% TRAVASOL AMINO ACID INJECTION WITHOUT ELECTROLYTES IN 25% DEXTROSE | baxter corporation clintec nutrition division | 02142244 | Solution - Intravenous | 290 MG / 100 ML | 12/31/1996 |
| 2.5% TRAVASOL AMINO ACID INJECTION WITH ELECTROLYTES IN 10% DEXTROSE CLINIMIX | baxter corporation clintec nutrition division | 02013975 | Solution - Intravenous | 115 MG / 100 ML | 12/31/1993 |
| CLINIMIX E | baxter corporation | 02013967 | Solution - Intravenous | 230 MG / 100 ML | 12/31/1993 |
| 5% TRAVASOL AMINO ACID INJECTION WITHOUT ELECTROLYTES IN 20% DEXTROSE | baxter corporation clintec nutrition division | 02142252 | Solution - Intravenous | 290 MG / 100 ML | 12/31/1996 |
| 5% TRAVASOL AMINO ACID INJECTION WITH ELECTROLYTES IN 20% DEXTROSE | baxter corporation clintec nutrition division | 02142368 | Solution - Intravenous | 290 MG / 100 ML | 12/31/1996 |
| 4.25% TRAVASOL AMINO ACID INJECTION WITHOUT ELECTROLYTES IN 25% DEXTROSE | baxter corporation clintec nutrition division | 02142295 | Solution - Intravenous | 246.5 MG / 100 ML | 12/31/1996 |
CIMA AEMPS Drug Approvals
Approved Product | Company | Registration Number | Pharmaceutical Form | Prescription Type | Status |
|---|---|---|---|---|---|
| No CIMA AEMPS (Spain) approvals found for this drug. | |||||
Philippines FDA Drug Approvals
Approved Product | Company | License Number | Dosage Form | Strength | Approval Date |
|---|---|---|---|---|---|
| No Philippines FDA approvals found for this drug. | |||||
Saudi SFDA Drug Approvals
Approved Product | Company | License Number | Dosage Form | Strength | Approval Date |
|---|---|---|---|---|---|
| No Saudi SFDA approvals found for this drug. | |||||
Malaysia NPRA Drug Approvals
Approved Product | Company | Registration Number | Dosage Form | Strength | Approval Date |
|---|---|---|---|---|---|
| No Malaysia NPRA approvals found for this drug. | |||||
UK EMC Drug Information
Medicine Name | MA Holder | MA Number | Pharmaceutical Form | Active Ingredient | Authorization Date |
|---|---|---|---|---|---|
| No UK EMC drug information found for this drug. | |||||
Help Us Improve
Your feedback helps us provide better drug information and insights.